$PFSA

Profusa (PFSA) sponsor’s $1.3M debt swap nears half the stock

Profusa (PFSA) sponsor NorthView converted $1.3M debt into 301,991 shares, now owning ~49.9% post reverse stock split. The conversion was per a modified agreement, with shares acquired at $1.07 each.

Original reporting
Published Aug 20, 2026, 12:41 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$PFSA
Neutral
high confidence
Mentioned
$PFSA
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PFSANeutralMed
01

Why it matters

The filing reveals a major shift in capital structure and control, likely influencing short-term price dynamics.

02

Market read

Ownership consolidation may affect liquidity and governance, prompting trader interest.

03

What to watch

Potential future dilution if additional financing is needed.

Relevance 7/10Novelty 8/10Timing: post-conversion August 2026

Background

Profusa filed a Schedule 13D showing sponsor's debt-to-equity conversion and near-50% ownership after a 1-for-4 reverse split.

Company-level read

Ticker impact

$PFSANeutralHigh confidence
Context

Sponsor converted $1.29M debt into ~302k shares, now holding ~50% of Profusa after reverse split.

Expected impact

Potential short-term volatility with possible modest upside as control is clarified.

Evidence & confidence

13D filing is first public disclosure of a large stake; market will reassess governance and liquidity.

Market effects

Highlights sponsor-driven financing in biotech sector.

US biotech microcap may see increased attention from activist investors.

Limited to Profusa shareholders and biotech niche.

Counterpoint

High concentration could deter new investors fearing limited float.

Key entities

  • Profusa, Inc.

    Biotech firm undergoing sponsor-driven ownership consolidation.

  • NorthView Sponsor I, LLC

    Sponsor converting debt into equity, now holds ~50% of Profusa.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001859807 0001859807 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.

$GSLow

Appleby Acts As Counsel To Goldman Sachs

Appleby served as legal counsel to Goldman Sachs in setting up West Grove Re, a Bermuda-based reinsurance sidecar. Goldman Sachs and Talcott Financial Group launched the entity to invest in the U.S. annuity market, raising around $1 billion in capital. Goldman Sachs and its clients, along with Talcott, made equity commitments.